Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription


1 Ann Intern Med
1 Arch Virol
1 Clin Infect Dis
1 Infect Immun
1 J Infect
2 J Infect Dis
1 J Virol
6 Lancet
2 Nat Immunol
1 PLoS Med
4 PLoS One
1 Proc Natl Acad Sci U S A
32 Vaccine
1 Virus Res

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Ann Intern Med

  1. LAINE C, Qaseem A, Moyer DV
    Putting Adult Vaccine Recommendations Into Action.
    Ann Intern Med. 2024 Feb 13. doi: 10.7326/M24-0242.

    Arch Virol

  2. TAFFAREL AI, Barrios Benito MY, Hung VV, Cardillo S, et al
    Foot-and-mouth disease virus strains isolated in Vietnam during 2010-2019: genetic characterization and antigenic relatedness to the Euro SA vaccine.
    Arch Virol. 2024;169:44.
    PubMed         Abstract available


  3. HEALY A
    Measles: increasing vaccine uptake is vital in preventing outbreaks.
    BMJ. 2024;384:q402.

  4. LOPEZ-BELTRAN A, Cookson MS, Guercio BJ, Cheng L, et al
    Advances in diagnosis and treatment of bladder cancer.
    BMJ. 2024;384:e076743.
    PubMed         Abstract available

  5. BEDFORD H, Elliman D
    Measles rates are rising again.
    BMJ. 2024;384:q259.

    Clin Infect Dis

  6. HOFMEYER KA, Ventura CL, Armstrong KL, Houchens CR, et al
    Project NexGen: Developing the Next Generation of COVID-19 Vaccines and Therapeutics to Respond to the Present and Prepare for the Future.
    Clin Infect Dis. 2024 Feb 13:ciae073. doi: 10.1093.
    PubMed         Abstract available

    Infect Immun

  7. KHAKHUM N, Baruch-Torres N, Stockton JL, Chapartegui-Gonzalez I, et al
    Decoration of Burkholderia Hcp1 protein to virus-like particles as a vaccine delivery platform.
    Infect Immun. 2024 Feb 14:e0001924. doi: 10.1128/iai.00019.
    PubMed         Abstract available

    J Infect

  8. KALKERI R, Zhu M, Cloney-Clark S, Plested JS, et al
    Altered IgG4 Antibody Response to Repeated mRNA versus Recombinant Protein SARS-CoV-2 Vaccines.
    J Infect. 2024 Feb 13:106119. doi: 10.1016/j.jinf.2024.106119.

    J Infect Dis

  9. CHALKIAS S, McGhee N, Whatley JL, Essink B, et al
    Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines.
    J Infect Dis. 2024 Feb 13:jiae067. doi: 10.1093.
    PubMed         Abstract available

  10. DAVIES KA, Welch SR, Jain S, Sorvillo TE, et al
    Fluorescent and Bioluminescent Reporter Mouse-Adapted Ebola Viruses Maintain Pathogenicity and Can Be Visualized in Vivo.
    J Infect Dis. 2023;228.
    PubMed         Abstract available

    J Virol

  11. NIE L, Huang Y, Cheng Z, Luo H, et al
    An intranasal influenza virus vector vaccine protects against Helicobacter pylori in mice.
    J Virol. 2024 Feb 15:e0192323. doi: 10.1128/jvi.01923.
    PubMed         Abstract available


  12. Undervaccination and severe COVID-19 outcomes: meta-analysis of national cohort studies in England, Northern Ireland, Scotland, and Wales.
    Lancet. 2024 Jan 12:S0140-6736(23)02467-4. doi: 10.1016/S0140-6736(23)02467.
    PubMed         Abstract available

    Malaria vaccines: a test for global health.
    Lancet. 2024;403:503.

  14. NNAJI CA, Amaechi UA, Wiysonge CS
    R21/Matrix-M vaccine: optimising supply, maximising impact.
    Lancet. 2024;403:525.

  15. DOPPEN M, Kearns C, Hills T, Weatherall M, et al
    Intramuscular vaccination needle length: a call to arms.
    Lancet. 2024;403:528-529.

  16. ALBIN RL
    Vaccination and the defence of democracy.
    Lancet. 2024;403:529.

  17. CARPIANO RM, Callahan T, Elharake JA, Hotez P, et al
    Vaccination and the defence of democracy - Authors' reply.
    Lancet. 2024;403:529-530.

    Nat Immunol

  18. YING B, Darling TL, Desai P, Liang CY, et al
    Mucosal vaccine-induced cross-reactive CD8(+) T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection.
    Nat Immunol. 2024 Feb 9. doi: 10.1038/s41590-024-01743.
    PubMed         Abstract available

  19. YING B, Darling TL, Desai P, Liang CY, et al
    Author Correction: Mucosal vaccine-induced cross-reactive CD8(+) T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection.
    Nat Immunol. 2024 Feb 15. doi: 10.1038/s41590-024-01781.

    PLoS Med

  20. NICKEL NC, Phillips-Beck W, Enns JE, Ekuma O, et al
    COVID-19 diagnostic testing and vaccinations among First Nations in Manitoba: A nations-based retrospective cohort study using linked administrative data, 2020-2021.
    PLoS Med. 2024;21:e1004348.
    PubMed         Abstract available

    PLoS One

  21. VEPACHEDU S, Nurzenska A, Lohiniva AL, Hudi AH, et al
    Understanding COVID-19 vaccination behaviors and intentions in Ghana: A Behavioral Insights (BI) study.
    PLoS One. 2024;19:e0292532.
    PubMed         Abstract available

  22. MANZEMU DG, Opara JPA, Kasai ET, Mumbere M, et al
    Rotavirus and adenovirus infections in children with acute gastroenteritis after introducing the Rotasiil(R) vaccine in Kisangani, Democratic Republic of the Congo.
    PLoS One. 2024;19:e0297219.
    PubMed         Abstract available

  23. PELLETIER C, Gagnon D, Dube E
    "It's not that I don't trust vaccines, I just don't think I need them": Perspectives on COVID-19 vaccination.
    PLoS One. 2024;19:e0293643.
    PubMed         Abstract available

  24. TAKEBAYASHI M, Namba M, Kaneda Y, Koyama T, et al
    How can we promote vaccination of the mass population?-Lessons from the COVID-19 vaccination defaults.
    PLoS One. 2024;19:e0298983.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  25. RAINS SA, Richards AS
    US state vaccine mandates did not influence COVID-19 vaccination rates but reduced uptake of COVID-19 boosters and flu vaccines compared to bans on vaccine restrictions.
    Proc Natl Acad Sci U S A. 2024;121:e2313610121.
    PubMed         Abstract available


  26. ROWLEY F, Cottrell S, Howard C, Meredith N, et al
    Use of invitations and reminders are associated with higher levels of Herpes zoster (shingles) vaccination uptake. A cross-sectional survey of general practices in Wales, and ecological analysis of uptake data, 2022.
    Vaccine. 2024 Feb 14:S0264-410X(24)00193-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  27. ACEVES-SANCHEZ MJ, Barrios-Payan JA, Segura-Cerda CA, Flores-Valdez MA, et al
    Erratum to "BCGDeltaBCG1419c and BCG differ in induction of autophagy, c-di-GMP content, proteome, and progression of lung pathology in Mycobacterium tuberculosis HN878-infected male BALB/c mice" [Vaccine 41(26) (2023) 3824-3835].
    Vaccine. 2024 Feb 14:S0264-410X(24)00176-2. doi: 10.1016/j.vaccine.2024.

  28. DUGGAR C, Santoli JM, Noblit C, Moore LB, et al
    U.S. COVID-19 vaccine distribution strategies, systems, performance, and lessons learned, December 2020 - May 2023.
    Vaccine. 2024 Feb 14:S0264-410X(24)00167-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  29. BORYS D, Rupp R, Smulders R, Chichili GR, et al
    Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial.
    Vaccine. 2024 Feb 14:S0264-410X(24)00145-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  30. BATHEJA A, Balkrishnan R
    Rhode Island as a model for promoting flu vaccination in the United States.
    Vaccine. 2024 Feb 14:S0264-410X(24)00161-0. doi: 10.1016/j.vaccine.2024.

  31. OKOLI GN, Righolt CH, Zhang G, Van Caeseele P, et al
    A population-based, province-wide, record-linkage interrupted time series analysis of impact of the universal seasonal influenza vaccination policy on seasonal influenza vaccine uptake among 5-64-year-olds in the province of Manitoba, Canada.
    Vaccine. 2024 Feb 14:S0264-410X(24)00104-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  32. DONATO F, Pilotto A, Foca E, Tresoldi M, et al
    The impact of time since SARS-Cov-2 vaccination, age, sex and comorbidities on COVID-19 outcome in hospitalized patients with SARS-CoV-2 infection.
    Vaccine. 2024 Feb 13:S0264-410X(24)00147-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  33. HEARN EB, Kehinde G, Sambamoorthi U
    Food insecurity and COVID-19 vaccine hesitancy among adults in the United States (US).
    Vaccine. 2024 Feb 13:S0264-410X(24)00102-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  34. PENG Y, Yan H, Zhang J, Peng R, et al
    Potent immune responses against thermostable Foot-and-Mouth disease virus VP1 nanovaccine adjuvanted with polymeric thermostable scaffold.
    Vaccine. 2024;42:732-737.
    PubMed         Abstract available

  35. SMITH TC, Gorski DH
    Infertility: A common target of antivaccine misinformation campaigns.
    Vaccine. 2024;42:924-929.
    PubMed         Abstract available

  36. AMINZADEH A, Hilgers L, Paul Platenburg P, Riou M, et al
    Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant.
    Vaccine. 2024 Feb 8:S0264-410X(24)00101-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  37. SERRANO-MAYORGA CC, Ibanez-Prada ED, Restrepo-Martinez JM, Garcia-Gallo E, et al
    The potential impact of PCV-13, PCV-15 and PCV-20 vaccines in Colombia.
    Vaccine. 2024 Feb 8:S0264-410X(24)00109-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  38. WADAPURKAR R, Singh S, Singh A
    Leveraging the immunoinformatics approach for designing the SARS-CoV-2 omicron-specific antigenic cassette of mRNA vaccine.
    Vaccine. 2024 Feb 8:S0264-410X(24)00111-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  39. GRIMA AA, Kwong JC, Richard L, Reid J, et al
    The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.
    Vaccine. 2024 Jan 17:S0264-410X(24)00023-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  40. BUEKENS P, Berrueta M, Ciapponi A, Bardach A, et al
    Safe in pregnancy: A global living systematic review and meta-analysis of COVID-19 vaccines in pregnancy.
    Vaccine. 2024 Feb 9:S0264-410X(24)00158-0. doi: 10.1016/j.vaccine.2024.

  41. FORTUNATO F, Musco A, Iannelli G, Meola M, et al
    Effectiveness of the combined MMRV Priorix-Tetra vaccine against varicella in a large Italian region: A case-control study.
    Vaccine. 2024 Feb 9:S0264-410X(24)00146-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  42. MCDERMID P, Blazek K, Mougin N, Thomson A, et al
    Attitudes and behaviors of maternal Tdap vaccination in Panama, Peru, and Colombia: An international cross-sectional study.
    Vaccine. 2024 Feb 13:S0264-410X(24)00143-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  43. LI Y, Sun X, Fu Y, You X, et al
    Literature review to identify evidence of secondary transmission of pentavalent human-bovine reassortant rotavirus vaccine (RV5) strains to unvaccinated subjects.
    Vaccine. 2024 Feb 13:S0264-410X(24)00107-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  44. BHARUCHA T, Gangadharan B, Clarke R, Fernandez LG, et al
    Repurposing rapid diagnostic tests to detect falsified vaccines in supply chains.
    Vaccine. 2024 Feb 13:S0264-410X(24)00019-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  45. KLASSEN AC, Lee G, Chiang S, Murray R, et al
    Did the COVID-19 experience change U.S. parents' attitudes towards HPV vaccination? Results from a national survey.
    Vaccine. 2024 Feb 14:S0264-410X(24)00142-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  46. MORGAN HJ, Clothier HJ, Sepulveda Kattan G, Boyd JH, et al
    Acute disseminated encephalomyelitis and transverse myelitis following COVID-19 vaccination - A self-controlled case series analysis.
    Vaccine. 2024 Feb 12:S0264-410X(24)00126-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  47. MABALE MAA, Tejero LMS, Montes LA, Collante MTM, et al
    Implications of information heard about Dengvaxia on Filipinos' perception on vaccination.
    Vaccine. 2024 Feb 12:S0264-410X(24)00123-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  48. AMDISEN L, Pedersen L, Abildgaard N, Benn CS, et al
    The coverage of influenza vaccination and predictors of influenza non-vaccination in Danish cancer patients: A nationwide register-based cohort study.
    Vaccine. 2024 Feb 12:S0264-410X(24)00155-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  49. FAKSOVA K, Walsh D, Jiang Y, Griffin J, et al
    COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
    Vaccine. 2024 Feb 12:S0264-410X(24)00127-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  50. MANNING J, Manna S, Dunne EM, Bongcaron V, et al
    Immunization with a whole cell vaccine reduces pneumococcal nasopharyngeal density and shedding, and middle ear infection in mice.
    Vaccine. 2024 Feb 12:S0264-410X(24)00131-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  51. VALENTIN J, Ingrao F, Rauw F, Lambrecht B, et al
    Protection conferred by an H5 DNA vaccine against highly pathogenic avian influenza in chickens: The effect of vaccination schedules.
    Vaccine. 2024 Feb 12:S0264-410X(23)01422-6. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  52. DE WALS P, Desjardins M
    Minimal interval for the administration of a pneumococcal polysaccharide vaccine following the administration of a pneumococcal conjugate vaccine.
    Vaccine. 2024 Feb 12:S0264-410X(24)00163-4. doi: 10.1016/j.vaccine.2024.

  53. LIJESKIC O, Bauman N, Markovic M, Srbljanovic J, et al
    SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost.
    Vaccine. 2024 Feb 10:S0264-410X(24)00110-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  54. WHITAKER HJ, Hassell K, Hoschler K, Power L, et al
    Influenza vaccination during the 2021/22 season: A data-linkage test-negative case-control study of effectiveness against influenza requiring emergency care in England and serological analysis of primary care patients.
    Vaccine. 2024 Feb 10:S0264-410X(24)00150-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  55. MARKOWITZ LE, Hopkins RH Jr, Broder KR, Lee GM, et al
    COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic.
    Vaccine. 2024 Feb 9:S0264-410X(23)01505-0. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  56. WEI J, Tan TC, Moa AM, MacIntyre CR, et al
    Cost-benefit of influenza vaccination in preventing sudden cardiac arrest amongst Australian adults.
    Vaccine. 2024 Feb 9:S0264-410X(24)00154-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  57. NGUYEN KH, Chen S, Zhao R, Vasudevan L, et al
    Vaccination patterns and up-to-date status of children 19-35 months, 2011-2021.
    Vaccine. 2024 Feb 9:S0264-410X(24)00122-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

    Virus Res

  58. CHOWDHURY IR, Viktorova E, Samal SK, Belov GA, et al
    The effect of 5' and 3' non-translated regions on the expression of a transgene from a Newcastle disease virus vector.
    Virus Res. 2024;341:199309.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.